http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2025, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 14 May 2025 08:31:36 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Corporate+News/Tivic+Health+Systems+%28TIVC%29+enters+GMP+manufacturing+agreement+with+Scorpius+Bio/24793343.html <p><span data-silink="1" target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.tivichealth.com%2F&amp;esheet=54254631&amp;newsitemid=20250514637661&amp;lan=en-US&amp;anchor=Tivic+Health%26%23174%3B+Systems%2C+Inc.&amp;index=1&amp;md5=d4aba0585fc1d150035e1c00a7f0e1c0" shape="rect">Tivic Health® Systems, Inc.</span> (Nasdaq: TIVC), a diversified therapeutics company, announced today it has entered a definitive agreement with Scorpius BioManufacturing to complete the GMP manufacturing validation of the lead candidate from its TLR5 program, Entolimod™, for treatment of Acute Radiation Syndrome, or ARS, in preparation for filing a Biological Licensing application, or BLA, with the U.S. Food & Drug Administration.</p><p>Scorpius BioManufacturing, Inc. is an integrated contract development and manufacturing organization (CDMO) and subsidiary of Scorpius Holdings Inc. (OTC:SCPX), which will be the primary U.S. manufacturer for Entolimod™. Scorpius plans to utilize its scientific and http://www.streetinsider.com/Corporate+News/Tivic+Health+Systems+%28TIVC%29+enters+GMP+manufacturing+agreement+with+Scorpius+Bio/24793343.html Wed, 14 May 2025 08:31:36 -0400 SCPX TIVC http://www.streetinsider.com/Corporate+News/Tivic+Health+Systems+%28TIVC%29+enters+GMP+manufacturing+agreement+with+Scorpius+Bio/24793343.html <p><span data-silink="1" target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.tivichealth.com%2F&amp;esheet=54254631&amp;newsitemid=20250514637661&amp;lan=en-US&amp;anchor=Tivic+Health%26%23174%3B+Systems%2C+Inc.&amp;index=1&amp;md5=d4aba0585fc1d150035e1c00a7f0e1c0" shape="rect">Tivic Health® Systems, Inc.</span> (Nasdaq: TIVC), a diversified therapeutics company, announced today it has entered a definitive agreement with Scorpius BioManufacturing to complete the GMP manufacturing validation of the lead candidate from its TLR5 program, Entolimod™, for treatment of Acute Radiation Syndrome, or ARS, in preparation for filing a Biological Licensing application, or BLA, with the U.S. Food & Drug Administration.</p><p>Scorpius BioManufacturing, Inc. is an integrated contract development and manufacturing organization (CDMO) and subsidiary of Scorpius Holdings Inc. (OTC:SCPX), which will be the primary U.S. manufacturer for Entolimod™. Scorpius plans to utilize its scientific and http://www.streetinsider.com/Corporate+News/Tivic+Health+Systems+%28TIVC%29+enters+GMP+manufacturing+agreement+with+Scorpius+Bio/24793343.html Wed, 14 May 2025 08:31:36 -0400 SCPX TIVC http://www.streetinsider.com/Press+Releases/Tivic+Health+Enters+GMP+Manufacturing+Validation+Agreement+with+Scorpius+BioManufacturing+in+Preparation+for+FDA+Submission/24793293.html <p> FREMONT, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.tivichealth.com%2F&amp;esheet=54254631&amp;newsitemid=20250514637661&amp;lan=en-US&amp;anchor=Tivic+Health%26%23174%3B+Systems%2C+Inc.&amp;index=1&amp;md5=d4aba0585fc1d150035e1c00a7f0e1c0" shape="rect">Tivic Health® Systems, Inc.</a> (Nasdaq: TIVC), a diversified therapeutics company, announced today it has entered a definitive agreement with Scorpius BioManufacturing to complete the GMP manufacturing validation of the lead candidate from its TLR5 program, Entolimod™, for treatment of Acute Radiation Syndrome, or ARS, in preparation for filing a Biological Licensing application, or BLA, with the U.S. Food &amp; Drug Administration. </p><p> Scorpius BioManufacturing, Inc. is an integrated contract development and manufacturing organization (CDMO) and subsidiary of Scorpius Holdings Inc. (OTC:SCPX), which will be the primary U.S. manufacturer for Entolimod™. Scorpius plans http://www.streetinsider.com/Press+Releases/Tivic+Health+Enters+GMP+Manufacturing+Validation+Agreement+with+Scorpius+BioManufacturing+in+Preparation+for+FDA+Submission/24793293.html Wed, 14 May 2025 08:30:00 -0400 A.06822034 A.40958841 O.20026344 O.36670513 O.52936745 SCPX TIVC http://www.streetinsider.com/Press+Releases/Tivic+Health+Enters+GMP+Manufacturing+Validation+Agreement+with+Scorpius+BioManufacturing+in+Preparation+for+FDA+Submission/24793293.html <p> FREMONT, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.tivichealth.com%2F&amp;esheet=54254631&amp;newsitemid=20250514637661&amp;lan=en-US&amp;anchor=Tivic+Health%26%23174%3B+Systems%2C+Inc.&amp;index=1&amp;md5=d4aba0585fc1d150035e1c00a7f0e1c0" shape="rect">Tivic Health® Systems, Inc.</a> (Nasdaq: TIVC), a diversified therapeutics company, announced today it has entered a definitive agreement with Scorpius BioManufacturing to complete the GMP manufacturing validation of the lead candidate from its TLR5 program, Entolimod™, for treatment of Acute Radiation Syndrome, or ARS, in preparation for filing a Biological Licensing application, or BLA, with the U.S. Food &amp; Drug Administration. </p><p> Scorpius BioManufacturing, Inc. is an integrated contract development and manufacturing organization (CDMO) and subsidiary of Scorpius Holdings Inc. (OTC:SCPX), which will be the primary U.S. manufacturer for Entolimod™. Scorpius plans http://www.streetinsider.com/Press+Releases/Tivic+Health+Enters+GMP+Manufacturing+Validation+Agreement+with+Scorpius+BioManufacturing+in+Preparation+for+FDA+Submission/24793293.html Wed, 14 May 2025 08:30:00 -0400 A.06822034 A.40958841 O.20026344 O.36670513 O.52936745 SCPX TIVC http://www.streetinsider.com/Press+Releases/Tivic+Health+Enters+GMP+Manufacturing+Validation+Agreement+with+Scorpius+BioManufacturing+in+Preparation+for+FDA+Submission/24793293.html <p> FREMONT, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.tivichealth.com%2F&amp;esheet=54254631&amp;newsitemid=20250514637661&amp;lan=en-US&amp;anchor=Tivic+Health%26%23174%3B+Systems%2C+Inc.&amp;index=1&amp;md5=d4aba0585fc1d150035e1c00a7f0e1c0" shape="rect">Tivic Health® Systems, Inc.</a> (Nasdaq: TIVC), a diversified therapeutics company, announced today it has entered a definitive agreement with Scorpius BioManufacturing to complete the GMP manufacturing validation of the lead candidate from its TLR5 program, Entolimod™, for treatment of Acute Radiation Syndrome, or ARS, in preparation for filing a Biological Licensing application, or BLA, with the U.S. Food &amp; Drug Administration. </p><p> Scorpius BioManufacturing, Inc. is an integrated contract development and manufacturing organization (CDMO) and subsidiary of Scorpius Holdings Inc. (OTC:SCPX), which will be the primary U.S. manufacturer for Entolimod™. Scorpius plans http://www.streetinsider.com/Press+Releases/Tivic+Health+Enters+GMP+Manufacturing+Validation+Agreement+with+Scorpius+BioManufacturing+in+Preparation+for+FDA+Submission/24793293.html Wed, 14 May 2025 08:30:00 -0400 A.06822034 A.40958841 O.20026344 O.36670513 O.52936745 SCPX TIVC http://www.streetinsider.com/Press+Releases/Tivic+Health+Enters+GMP+Manufacturing+Validation+Agreement+with+Scorpius+BioManufacturing+in+Preparation+for+FDA+Submission/24793293.html <p> FREMONT, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.tivichealth.com%2F&amp;esheet=54254631&amp;newsitemid=20250514637661&amp;lan=en-US&amp;anchor=Tivic+Health%26%23174%3B+Systems%2C+Inc.&amp;index=1&amp;md5=d4aba0585fc1d150035e1c00a7f0e1c0" shape="rect">Tivic Health® Systems, Inc.</a> (Nasdaq: TIVC), a diversified therapeutics company, announced today it has entered a definitive agreement with Scorpius BioManufacturing to complete the GMP manufacturing validation of the lead candidate from its TLR5 program, Entolimod™, for treatment of Acute Radiation Syndrome, or ARS, in preparation for filing a Biological Licensing application, or BLA, with the U.S. Food &amp; Drug Administration. </p><p> Scorpius BioManufacturing, Inc. is an integrated contract development and manufacturing organization (CDMO) and subsidiary of Scorpius Holdings Inc. (OTC:SCPX), which will be the primary U.S. manufacturer for Entolimod™. Scorpius plans http://www.streetinsider.com/Press+Releases/Tivic+Health+Enters+GMP+Manufacturing+Validation+Agreement+with+Scorpius+BioManufacturing+in+Preparation+for+FDA+Submission/24793293.html Wed, 14 May 2025 08:30:00 -0400 A.06822034 A.40958841 O.20026344 O.36670513 O.52936745 SCPX TIVC http://www.streetinsider.com/Press+Releases/Tivic+Health+Enters+GMP+Manufacturing+Validation+Agreement+with+Scorpius+BioManufacturing+in+Preparation+for+FDA+Submission/24793293.html <p> FREMONT, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.tivichealth.com%2F&amp;esheet=54254631&amp;newsitemid=20250514637661&amp;lan=en-US&amp;anchor=Tivic+Health%26%23174%3B+Systems%2C+Inc.&amp;index=1&amp;md5=d4aba0585fc1d150035e1c00a7f0e1c0" shape="rect">Tivic Health® Systems, Inc.</a> (Nasdaq: TIVC), a diversified therapeutics company, announced today it has entered a definitive agreement with Scorpius BioManufacturing to complete the GMP manufacturing validation of the lead candidate from its TLR5 program, Entolimod™, for treatment of Acute Radiation Syndrome, or ARS, in preparation for filing a Biological Licensing application, or BLA, with the U.S. Food &amp; Drug Administration. </p><p> Scorpius BioManufacturing, Inc. is an integrated contract development and manufacturing organization (CDMO) and subsidiary of Scorpius Holdings Inc. (OTC:SCPX), which will be the primary U.S. manufacturer for Entolimod™. Scorpius plans http://www.streetinsider.com/Press+Releases/Tivic+Health+Enters+GMP+Manufacturing+Validation+Agreement+with+Scorpius+BioManufacturing+in+Preparation+for+FDA+Submission/24793293.html Wed, 14 May 2025 08:30:00 -0400 A.06822034 A.40958841 O.20026344 O.36670513 O.52936745 SCPX TIVC http://www.streetinsider.com/Press+Releases/Tivic+Health+Enters+GMP+Manufacturing+Validation+Agreement+with+Scorpius+BioManufacturing+in+Preparation+for+FDA+Submission/24793293.html <p> FREMONT, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.tivichealth.com%2F&amp;esheet=54254631&amp;newsitemid=20250514637661&amp;lan=en-US&amp;anchor=Tivic+Health%26%23174%3B+Systems%2C+Inc.&amp;index=1&amp;md5=d4aba0585fc1d150035e1c00a7f0e1c0" shape="rect">Tivic Health® Systems, Inc.</a> (Nasdaq: TIVC), a diversified therapeutics company, announced today it has entered a definitive agreement with Scorpius BioManufacturing to complete the GMP manufacturing validation of the lead candidate from its TLR5 program, Entolimod™, for treatment of Acute Radiation Syndrome, or ARS, in preparation for filing a Biological Licensing application, or BLA, with the U.S. Food &amp; Drug Administration. </p><p> Scorpius BioManufacturing, Inc. is an integrated contract development and manufacturing organization (CDMO) and subsidiary of Scorpius Holdings Inc. (OTC:SCPX), which will be the primary U.S. manufacturer for Entolimod™. Scorpius plans http://www.streetinsider.com/Press+Releases/Tivic+Health+Enters+GMP+Manufacturing+Validation+Agreement+with+Scorpius+BioManufacturing+in+Preparation+for+FDA+Submission/24793293.html Wed, 14 May 2025 08:30:00 -0400 A.06822034 A.40958841 O.20026344 O.36670513 O.52936745 SCPX TIVC http://www.streetinsider.com/Press+Releases/Tivic+Health+Enters+GMP+Manufacturing+Validation+Agreement+with+Scorpius+BioManufacturing+in+Preparation+for+FDA+Submission/24793293.html <p> FREMONT, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.tivichealth.com%2F&amp;esheet=54254631&amp;newsitemid=20250514637661&amp;lan=en-US&amp;anchor=Tivic+Health%26%23174%3B+Systems%2C+Inc.&amp;index=1&amp;md5=d4aba0585fc1d150035e1c00a7f0e1c0" shape="rect">Tivic Health® Systems, Inc.</a> (Nasdaq: TIVC), a diversified therapeutics company, announced today it has entered a definitive agreement with Scorpius BioManufacturing to complete the GMP manufacturing validation of the lead candidate from its TLR5 program, Entolimod™, for treatment of Acute Radiation Syndrome, or ARS, in preparation for filing a Biological Licensing application, or BLA, with the U.S. Food &amp; Drug Administration. </p><p> Scorpius BioManufacturing, Inc. is an integrated contract development and manufacturing organization (CDMO) and subsidiary of Scorpius Holdings Inc. (OTC:SCPX), which will be the primary U.S. manufacturer for Entolimod™. Scorpius plans http://www.streetinsider.com/Press+Releases/Tivic+Health+Enters+GMP+Manufacturing+Validation+Agreement+with+Scorpius+BioManufacturing+in+Preparation+for+FDA+Submission/24793293.html Wed, 14 May 2025 08:30:00 -0400 A.06822034 A.40958841 O.20026344 O.36670513 O.52936745 SCPX TIVC http://www.streetinsider.com/Business+Wire/Tivic+Health+Enters+GMP+Manufacturing+Validation+Agreement+with+Scorpius+BioManufacturing+in+Preparation+for+FDA+Submission/24793293.html <p> FREMONT, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.tivichealth.com%2F&amp;esheet=54254631&amp;newsitemid=20250514637661&amp;lan=en-US&amp;anchor=Tivic+Health%26%23174%3B+Systems%2C+Inc.&amp;index=1&amp;md5=d4aba0585fc1d150035e1c00a7f0e1c0" shape="rect">Tivic Health® Systems, Inc.</a> (Nasdaq: TIVC), a diversified therapeutics company, announced today it has entered a definitive agreement with Scorpius BioManufacturing to complete the GMP manufacturing validation of the lead candidate from its TLR5 program, Entolimod™, for treatment of Acute Radiation Syndrome, or ARS, in preparation for filing a Biological Licensing application, or BLA, with the U.S. Food &amp; Drug Administration. </p><p> Scorpius BioManufacturing, Inc. is an integrated contract development and manufacturing organization (CDMO) and subsidiary of Scorpius Holdings Inc. (OTC:SCPX), which will be the primary U.S. manufacturer for Entolimod™. Scorpius plans http://www.streetinsider.com/Business+Wire/Tivic+Health+Enters+GMP+Manufacturing+Validation+Agreement+with+Scorpius+BioManufacturing+in+Preparation+for+FDA+Submission/24793293.html Wed, 14 May 2025 08:30:00 -0400 A.06822034 A.40958841 O.20026344 O.36670513 O.52936745 SCPX TIVC http://www.streetinsider.com/Business+Wire/Tivic+Health+Enters+GMP+Manufacturing+Validation+Agreement+with+Scorpius+BioManufacturing+in+Preparation+for+FDA+Submission/24793293.html <p> FREMONT, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.tivichealth.com%2F&amp;esheet=54254631&amp;newsitemid=20250514637661&amp;lan=en-US&amp;anchor=Tivic+Health%26%23174%3B+Systems%2C+Inc.&amp;index=1&amp;md5=d4aba0585fc1d150035e1c00a7f0e1c0" shape="rect">Tivic Health® Systems, Inc.</a> (Nasdaq: TIVC), a diversified therapeutics company, announced today it has entered a definitive agreement with Scorpius BioManufacturing to complete the GMP manufacturing validation of the lead candidate from its TLR5 program, Entolimod™, for treatment of Acute Radiation Syndrome, or ARS, in preparation for filing a Biological Licensing application, or BLA, with the U.S. Food &amp; Drug Administration. </p><p> Scorpius BioManufacturing, Inc. is an integrated contract development and manufacturing organization (CDMO) and subsidiary of Scorpius Holdings Inc. (OTC:SCPX), which will be the primary U.S. manufacturer for Entolimod™. Scorpius plans http://www.streetinsider.com/Business+Wire/Tivic+Health+Enters+GMP+Manufacturing+Validation+Agreement+with+Scorpius+BioManufacturing+in+Preparation+for+FDA+Submission/24793293.html Wed, 14 May 2025 08:30:00 -0400 A.06822034 A.40958841 O.20026344 O.36670513 O.52936745 SCPX TIVC http://www.streetinsider.com/Business+Wire/Tivic+Health+Enters+GMP+Manufacturing+Validation+Agreement+with+Scorpius+BioManufacturing+in+Preparation+for+FDA+Submission/24793293.html <p> FREMONT, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.tivichealth.com%2F&amp;esheet=54254631&amp;newsitemid=20250514637661&amp;lan=en-US&amp;anchor=Tivic+Health%26%23174%3B+Systems%2C+Inc.&amp;index=1&amp;md5=d4aba0585fc1d150035e1c00a7f0e1c0" shape="rect">Tivic Health® Systems, Inc.</a> (Nasdaq: TIVC), a diversified therapeutics company, announced today it has entered a definitive agreement with Scorpius BioManufacturing to complete the GMP manufacturing validation of the lead candidate from its TLR5 program, Entolimod™, for treatment of Acute Radiation Syndrome, or ARS, in preparation for filing a Biological Licensing application, or BLA, with the U.S. Food &amp; Drug Administration. </p><p> Scorpius BioManufacturing, Inc. is an integrated contract development and manufacturing organization (CDMO) and subsidiary of Scorpius Holdings Inc. (OTC:SCPX), which will be the primary U.S. manufacturer for Entolimod™. Scorpius plans http://www.streetinsider.com/Business+Wire/Tivic+Health+Enters+GMP+Manufacturing+Validation+Agreement+with+Scorpius+BioManufacturing+in+Preparation+for+FDA+Submission/24793293.html Wed, 14 May 2025 08:30:00 -0400 A.06822034 A.40958841 O.20026344 O.36670513 O.52936745 SCPX TIVC http://www.streetinsider.com/Business+Wire/Tivic+Health+Enters+GMP+Manufacturing+Validation+Agreement+with+Scorpius+BioManufacturing+in+Preparation+for+FDA+Submission/24793293.html <p> FREMONT, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.tivichealth.com%2F&amp;esheet=54254631&amp;newsitemid=20250514637661&amp;lan=en-US&amp;anchor=Tivic+Health%26%23174%3B+Systems%2C+Inc.&amp;index=1&amp;md5=d4aba0585fc1d150035e1c00a7f0e1c0" shape="rect">Tivic Health® Systems, Inc.</a> (Nasdaq: TIVC), a diversified therapeutics company, announced today it has entered a definitive agreement with Scorpius BioManufacturing to complete the GMP manufacturing validation of the lead candidate from its TLR5 program, Entolimod™, for treatment of Acute Radiation Syndrome, or ARS, in preparation for filing a Biological Licensing application, or BLA, with the U.S. Food &amp; Drug Administration. </p><p> Scorpius BioManufacturing, Inc. is an integrated contract development and manufacturing organization (CDMO) and subsidiary of Scorpius Holdings Inc. (OTC:SCPX), which will be the primary U.S. manufacturer for Entolimod™. Scorpius plans http://www.streetinsider.com/Business+Wire/Tivic+Health+Enters+GMP+Manufacturing+Validation+Agreement+with+Scorpius+BioManufacturing+in+Preparation+for+FDA+Submission/24793293.html Wed, 14 May 2025 08:30:00 -0400 A.06822034 A.40958841 O.20026344 O.36670513 O.52936745 SCPX TIVC http://www.streetinsider.com/Business+Wire/Tivic+Health+Enters+GMP+Manufacturing+Validation+Agreement+with+Scorpius+BioManufacturing+in+Preparation+for+FDA+Submission/24793293.html <p> FREMONT, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.tivichealth.com%2F&amp;esheet=54254631&amp;newsitemid=20250514637661&amp;lan=en-US&amp;anchor=Tivic+Health%26%23174%3B+Systems%2C+Inc.&amp;index=1&amp;md5=d4aba0585fc1d150035e1c00a7f0e1c0" shape="rect">Tivic Health® Systems, Inc.</a> (Nasdaq: TIVC), a diversified therapeutics company, announced today it has entered a definitive agreement with Scorpius BioManufacturing to complete the GMP manufacturing validation of the lead candidate from its TLR5 program, Entolimod™, for treatment of Acute Radiation Syndrome, or ARS, in preparation for filing a Biological Licensing application, or BLA, with the U.S. Food &amp; Drug Administration. </p><p> Scorpius BioManufacturing, Inc. is an integrated contract development and manufacturing organization (CDMO) and subsidiary of Scorpius Holdings Inc. (OTC:SCPX), which will be the primary U.S. manufacturer for Entolimod™. Scorpius plans http://www.streetinsider.com/Business+Wire/Tivic+Health+Enters+GMP+Manufacturing+Validation+Agreement+with+Scorpius+BioManufacturing+in+Preparation+for+FDA+Submission/24793293.html Wed, 14 May 2025 08:30:00 -0400 A.06822034 A.40958841 O.20026344 O.36670513 O.52936745 SCPX TIVC http://www.streetinsider.com/Business+Wire/Tivic+Health+Enters+GMP+Manufacturing+Validation+Agreement+with+Scorpius+BioManufacturing+in+Preparation+for+FDA+Submission/24793293.html <p> FREMONT, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.tivichealth.com%2F&amp;esheet=54254631&amp;newsitemid=20250514637661&amp;lan=en-US&amp;anchor=Tivic+Health%26%23174%3B+Systems%2C+Inc.&amp;index=1&amp;md5=d4aba0585fc1d150035e1c00a7f0e1c0" shape="rect">Tivic Health® Systems, Inc.</a> (Nasdaq: TIVC), a diversified therapeutics company, announced today it has entered a definitive agreement with Scorpius BioManufacturing to complete the GMP manufacturing validation of the lead candidate from its TLR5 program, Entolimod™, for treatment of Acute Radiation Syndrome, or ARS, in preparation for filing a Biological Licensing application, or BLA, with the U.S. Food &amp; Drug Administration. </p><p> Scorpius BioManufacturing, Inc. is an integrated contract development and manufacturing organization (CDMO) and subsidiary of Scorpius Holdings Inc. (OTC:SCPX), which will be the primary U.S. manufacturer for Entolimod™. Scorpius plans http://www.streetinsider.com/Business+Wire/Tivic+Health+Enters+GMP+Manufacturing+Validation+Agreement+with+Scorpius+BioManufacturing+in+Preparation+for+FDA+Submission/24793293.html Wed, 14 May 2025 08:30:00 -0400 A.06822034 A.40958841 O.20026344 O.36670513 O.52936745 SCPX TIVC http://www.streetinsider.com/Business+Wire/Tivic+Health+Enters+GMP+Manufacturing+Validation+Agreement+with+Scorpius+BioManufacturing+in+Preparation+for+FDA+Submission/24793293.html <p> FREMONT, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.tivichealth.com%2F&amp;esheet=54254631&amp;newsitemid=20250514637661&amp;lan=en-US&amp;anchor=Tivic+Health%26%23174%3B+Systems%2C+Inc.&amp;index=1&amp;md5=d4aba0585fc1d150035e1c00a7f0e1c0" shape="rect">Tivic Health® Systems, Inc.</a> (Nasdaq: TIVC), a diversified therapeutics company, announced today it has entered a definitive agreement with Scorpius BioManufacturing to complete the GMP manufacturing validation of the lead candidate from its TLR5 program, Entolimod™, for treatment of Acute Radiation Syndrome, or ARS, in preparation for filing a Biological Licensing application, or BLA, with the U.S. Food &amp; Drug Administration. </p><p> Scorpius BioManufacturing, Inc. is an integrated contract development and manufacturing organization (CDMO) and subsidiary of Scorpius Holdings Inc. (OTC:SCPX), which will be the primary U.S. manufacturer for Entolimod™. Scorpius plans http://www.streetinsider.com/Business+Wire/Tivic+Health+Enters+GMP+Manufacturing+Validation+Agreement+with+Scorpius+BioManufacturing+in+Preparation+for+FDA+Submission/24793293.html Wed, 14 May 2025 08:30:00 -0400 A.06822034 A.40958841 O.20026344 O.36670513 O.52936745 SCPX TIVC http://www.streetinsider.com/Press+Releases/Scorpius+Holdings+Provides+2024+Year-End+Business+Update%3B+Implements+Strategic+Cost+Reductions+and+Operational+Streamlining/24717976.html <p align="left">SAN ANTONIO, April 30, 2025 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=NLKPQj5YXIvdjAC7cVSc81A8FtfqwP9Y3nEMpEftVwLVCReAwTeG_TgDyuU46otIrHWHf2kFqBp5g7N7h7MKQ5H3FlTSCSZ-iMHZvaEi2cWu58zl69ww3fZmnlEbi4SF" rel="nofollow" target="_blank"><strong>Scorpius Holdings, Inc</strong></a><strong> (OTC:</strong> <strong>SCPX) </strong>(“Scorpius” or “the Company”), an integrated contract development and manufacturing organization (&quot;CDMO”), today provided strategic, financial, and operational updates for the year ended December 31, 2024.</p> <p>Jeff Wolf, CEO of Scorpius Holdings, Inc., stated, &quot;The current biotech funding environment has created real headwinds for many of our clients, particularly when it comes to advancing drug development and clinical trials. In response, we took decisive steps to streamline our operations, reduce our cost structure, and refocus on our core CDMO http://www.streetinsider.com/Press+Releases/Scorpius+Holdings+Provides+2024+Year-End+Business+Update%3B+Implements+Strategic+Cost+Reductions+and+Operational+Streamlining/24717976.html Wed, 30 Apr 2025 16:05:00 -0400 A.19655944 A.35376616 O.00051561 O.03307993 SCPX http://www.streetinsider.com/Press+Releases/Scorpius+Holdings+Provides+2024+Year-End+Business+Update%3B+Implements+Strategic+Cost+Reductions+and+Operational+Streamlining/24717976.html <p align="left">SAN ANTONIO, April 30, 2025 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=NLKPQj5YXIvdjAC7cVSc81A8FtfqwP9Y3nEMpEftVwLVCReAwTeG_TgDyuU46otIrHWHf2kFqBp5g7N7h7MKQ5H3FlTSCSZ-iMHZvaEi2cWu58zl69ww3fZmnlEbi4SF" rel="nofollow" target="_blank"><strong>Scorpius Holdings, Inc</strong></a><strong> (OTC:</strong> <strong>SCPX) </strong>(“Scorpius” or “the Company”), an integrated contract development and manufacturing organization (&quot;CDMO”), today provided strategic, financial, and operational updates for the year ended December 31, 2024.</p> <p>Jeff Wolf, CEO of Scorpius Holdings, Inc., stated, &quot;The current biotech funding environment has created real headwinds for many of our clients, particularly when it comes to advancing drug development and clinical trials. In response, we took decisive steps to streamline our operations, reduce our cost structure, and refocus on our core CDMO http://www.streetinsider.com/Press+Releases/Scorpius+Holdings+Provides+2024+Year-End+Business+Update%3B+Implements+Strategic+Cost+Reductions+and+Operational+Streamlining/24717976.html Wed, 30 Apr 2025 16:05:00 -0400 A.19655944 A.35376616 O.00051561 O.03307993 SCPX http://www.streetinsider.com/Press+Releases/Scorpius+Holdings+Provides+2024+Year-End+Business+Update%3B+Implements+Strategic+Cost+Reductions+and+Operational+Streamlining/24717976.html <p align="left">SAN ANTONIO, April 30, 2025 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=NLKPQj5YXIvdjAC7cVSc81A8FtfqwP9Y3nEMpEftVwLVCReAwTeG_TgDyuU46otIrHWHf2kFqBp5g7N7h7MKQ5H3FlTSCSZ-iMHZvaEi2cWu58zl69ww3fZmnlEbi4SF" rel="nofollow" target="_blank"><strong>Scorpius Holdings, Inc</strong></a><strong> (OTC:</strong> <strong>SCPX) </strong>(“Scorpius” or “the Company”), an integrated contract development and manufacturing organization (&quot;CDMO”), today provided strategic, financial, and operational updates for the year ended December 31, 2024.</p> <p>Jeff Wolf, CEO of Scorpius Holdings, Inc., stated, &quot;The current biotech funding environment has created real headwinds for many of our clients, particularly when it comes to advancing drug development and clinical trials. In response, we took decisive steps to streamline our operations, reduce our cost structure, and refocus on our core CDMO http://www.streetinsider.com/Press+Releases/Scorpius+Holdings+Provides+2024+Year-End+Business+Update%3B+Implements+Strategic+Cost+Reductions+and+Operational+Streamlining/24717976.html Wed, 30 Apr 2025 16:05:00 -0400 A.19655944 A.35376616 O.00051561 O.03307993 SCPX http://www.streetinsider.com/Press+Releases/Scorpius+Holdings+Provides+2024+Year-End+Business+Update%3B+Implements+Strategic+Cost+Reductions+and+Operational+Streamlining/24717976.html <p align="left">SAN ANTONIO, April 30, 2025 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=NLKPQj5YXIvdjAC7cVSc81A8FtfqwP9Y3nEMpEftVwLVCReAwTeG_TgDyuU46otIrHWHf2kFqBp5g7N7h7MKQ5H3FlTSCSZ-iMHZvaEi2cWu58zl69ww3fZmnlEbi4SF" rel="nofollow" target="_blank"><strong>Scorpius Holdings, Inc</strong></a><strong> (OTC:</strong> <strong>SCPX) </strong>(“Scorpius” or “the Company”), an integrated contract development and manufacturing organization (&quot;CDMO”), today provided strategic, financial, and operational updates for the year ended December 31, 2024.</p> <p>Jeff Wolf, CEO of Scorpius Holdings, Inc., stated, &quot;The current biotech funding environment has created real headwinds for many of our clients, particularly when it comes to advancing drug development and clinical trials. In response, we took decisive steps to streamline our operations, reduce our cost structure, and refocus on our core CDMO http://www.streetinsider.com/Press+Releases/Scorpius+Holdings+Provides+2024+Year-End+Business+Update%3B+Implements+Strategic+Cost+Reductions+and+Operational+Streamlining/24717976.html Wed, 30 Apr 2025 16:05:00 -0400 A.19655944 A.35376616 O.00051561 O.03307993 SCPX http://www.streetinsider.com/Press+Releases/Scorpius+Holdings+Provides+2024+Year-End+Business+Update%3B+Implements+Strategic+Cost+Reductions+and+Operational+Streamlining/24717976.html <p align="left">SAN ANTONIO, April 30, 2025 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=NLKPQj5YXIvdjAC7cVSc81A8FtfqwP9Y3nEMpEftVwLVCReAwTeG_TgDyuU46otIrHWHf2kFqBp5g7N7h7MKQ5H3FlTSCSZ-iMHZvaEi2cWu58zl69ww3fZmnlEbi4SF" rel="nofollow" target="_blank"><strong>Scorpius Holdings, Inc</strong></a><strong> (OTC:</strong> <strong>SCPX) </strong>(“Scorpius” or “the Company”), an integrated contract development and manufacturing organization (&quot;CDMO”), today provided strategic, financial, and operational updates for the year ended December 31, 2024.</p> <p>Jeff Wolf, CEO of Scorpius Holdings, Inc., stated, &quot;The current biotech funding environment has created real headwinds for many of our clients, particularly when it comes to advancing drug development and clinical trials. In response, we took decisive steps to streamline our operations, reduce our cost structure, and refocus on our core CDMO http://www.streetinsider.com/Press+Releases/Scorpius+Holdings+Provides+2024+Year-End+Business+Update%3B+Implements+Strategic+Cost+Reductions+and+Operational+Streamlining/24717976.html Wed, 30 Apr 2025 16:05:00 -0400 A.19655944 A.35376616 O.00051561 O.03307993 SCPX http://www.streetinsider.com/Globe+Newswire/Scorpius+Holdings+Provides+2024+Year-End+Business+Update%3B+Implements+Strategic+Cost+Reductions+and+Operational+Streamlining/24717976.html <p align="left">SAN ANTONIO, April 30, 2025 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=NLKPQj5YXIvdjAC7cVSc81A8FtfqwP9Y3nEMpEftVwLVCReAwTeG_TgDyuU46otIrHWHf2kFqBp5g7N7h7MKQ5H3FlTSCSZ-iMHZvaEi2cWu58zl69ww3fZmnlEbi4SF" rel="nofollow" target="_blank"><strong>Scorpius Holdings, Inc</strong></a><strong> (OTC:</strong> <strong>SCPX) </strong>(“Scorpius” or “the Company”), an integrated contract development and manufacturing organization (&quot;CDMO”), today provided strategic, financial, and operational updates for the year ended December 31, 2024.</p> <p>Jeff Wolf, CEO of Scorpius Holdings, Inc., stated, &quot;The current biotech funding environment has created real headwinds for many of our clients, particularly when it comes to advancing drug development and clinical trials. In response, we took decisive steps to streamline our operations, reduce our cost structure, and refocus on our core CDMO http://www.streetinsider.com/Globe+Newswire/Scorpius+Holdings+Provides+2024+Year-End+Business+Update%3B+Implements+Strategic+Cost+Reductions+and+Operational+Streamlining/24717976.html Wed, 30 Apr 2025 16:05:00 -0400 A.19655944 A.35376616 O.00051561 O.03307993 SCPX http://www.streetinsider.com/Globe+Newswire/Scorpius+Holdings+Provides+2024+Year-End+Business+Update%3B+Implements+Strategic+Cost+Reductions+and+Operational+Streamlining/24717976.html <p align="left">SAN ANTONIO, April 30, 2025 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=NLKPQj5YXIvdjAC7cVSc81A8FtfqwP9Y3nEMpEftVwLVCReAwTeG_TgDyuU46otIrHWHf2kFqBp5g7N7h7MKQ5H3FlTSCSZ-iMHZvaEi2cWu58zl69ww3fZmnlEbi4SF" rel="nofollow" target="_blank"><strong>Scorpius Holdings, Inc</strong></a><strong> (OTC:</strong> <strong>SCPX) </strong>(“Scorpius” or “the Company”), an integrated contract development and manufacturing organization (&quot;CDMO”), today provided strategic, financial, and operational updates for the year ended December 31, 2024.</p> <p>Jeff Wolf, CEO of Scorpius Holdings, Inc., stated, &quot;The current biotech funding environment has created real headwinds for many of our clients, particularly when it comes to advancing drug development and clinical trials. In response, we took decisive steps to streamline our operations, reduce our cost structure, and refocus on our core CDMO http://www.streetinsider.com/Globe+Newswire/Scorpius+Holdings+Provides+2024+Year-End+Business+Update%3B+Implements+Strategic+Cost+Reductions+and+Operational+Streamlining/24717976.html Wed, 30 Apr 2025 16:05:00 -0400 A.19655944 A.35376616 O.00051561 O.03307993 SCPX http://www.streetinsider.com/Globe+Newswire/Scorpius+Holdings+Provides+2024+Year-End+Business+Update%3B+Implements+Strategic+Cost+Reductions+and+Operational+Streamlining/24717976.html <p align="left">SAN ANTONIO, April 30, 2025 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=NLKPQj5YXIvdjAC7cVSc81A8FtfqwP9Y3nEMpEftVwLVCReAwTeG_TgDyuU46otIrHWHf2kFqBp5g7N7h7MKQ5H3FlTSCSZ-iMHZvaEi2cWu58zl69ww3fZmnlEbi4SF" rel="nofollow" target="_blank"><strong>Scorpius Holdings, Inc</strong></a><strong> (OTC:</strong> <strong>SCPX) </strong>(“Scorpius” or “the Company”), an integrated contract development and manufacturing organization (&quot;CDMO”), today provided strategic, financial, and operational updates for the year ended December 31, 2024.</p> <p>Jeff Wolf, CEO of Scorpius Holdings, Inc., stated, &quot;The current biotech funding environment has created real headwinds for many of our clients, particularly when it comes to advancing drug development and clinical trials. In response, we took decisive steps to streamline our operations, reduce our cost structure, and refocus on our core CDMO http://www.streetinsider.com/Globe+Newswire/Scorpius+Holdings+Provides+2024+Year-End+Business+Update%3B+Implements+Strategic+Cost+Reductions+and+Operational+Streamlining/24717976.html Wed, 30 Apr 2025 16:05:00 -0400 A.19655944 A.35376616 O.00051561 O.03307993 SCPX http://www.streetinsider.com/Globe+Newswire/Scorpius+Holdings+Provides+2024+Year-End+Business+Update%3B+Implements+Strategic+Cost+Reductions+and+Operational+Streamlining/24717976.html <p align="left">SAN ANTONIO, April 30, 2025 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=NLKPQj5YXIvdjAC7cVSc81A8FtfqwP9Y3nEMpEftVwLVCReAwTeG_TgDyuU46otIrHWHf2kFqBp5g7N7h7MKQ5H3FlTSCSZ-iMHZvaEi2cWu58zl69ww3fZmnlEbi4SF" rel="nofollow" target="_blank"><strong>Scorpius Holdings, Inc</strong></a><strong> (OTC:</strong> <strong>SCPX) </strong>(“Scorpius” or “the Company”), an integrated contract development and manufacturing organization (&quot;CDMO”), today provided strategic, financial, and operational updates for the year ended December 31, 2024.</p> <p>Jeff Wolf, CEO of Scorpius Holdings, Inc., stated, &quot;The current biotech funding environment has created real headwinds for many of our clients, particularly when it comes to advancing drug development and clinical trials. In response, we took decisive steps to streamline our operations, reduce our cost structure, and refocus on our core CDMO http://www.streetinsider.com/Globe+Newswire/Scorpius+Holdings+Provides+2024+Year-End+Business+Update%3B+Implements+Strategic+Cost+Reductions+and+Operational+Streamlining/24717976.html Wed, 30 Apr 2025 16:05:00 -0400 A.19655944 A.35376616 O.00051561 O.03307993 SCPX